We are used to fishing out and purifying compounds that constitute only a small % of a sample, such as in this case study where four manufacturing batch impurities were isolated and identified. Find out more at https://lnkd.in/ecAbdvW4
Hypha Discovery Ltd
Research Services
Milton Park, Abingdon, Oxfordshire 3,779 followers
Experts in synthesis, purification and ID of metabolites and derivatives for pharma and agrochemical companies worldwide
About us
Hypha Discovery is a specialist CRO with expertise in scalable synthesis, purification and structure elucidation of phase 1 and phase 2 metabolites using biotransformation and late-stage chemical synthesis techniques. We work with pharma and agrochemical companies globally to make even the most difficult-to-synthesise metabolites. Hypha are experts in purification and structure elucidation of small molecules by NMR spectroscopy, as well as the production of microbial products. Synthesis of metabolites of drugs and agrochemicals We create human and other mammalian phase 1 and phase 2 metabolites of drug candidates and agrochemicals at mg to gram scale for many of the top pharma and agrochemical companies. Metabolites produced from a variety of phase I reactions are accessible, including both CYP and non-CYP derived mechanisms in addition to conjugated metabolites such as N-, O– & acyl glucuronides and sulfates. We employ a number of techniques in our One-Stop Metabolite Shop to identify the best method for synthesis and scale-up: • Chemical synthesis • Recombinant enzymes using PolyCYPs and other enzymes • Microbial biotransformation • Mammalian tissues such as liver fractions (S9/microsomes) We can provide an end-to-end service including purification, structure elucidation using NMR spectroscopy, and certificates of analysis. Late stage functionalisation Multiple oxidised derivatives of lead compounds can be accessed in parallel from application of the PolyCYPs enzyme platform and our new late-stage chemical oxidation platform. These techniques generate molecules that have increased polarity together with the possibility of greater activity, better selectivity or improved DMPK properties than the parent compound. The process provides an opportunity for expanding chemical space to generate SAR information or to identify derivatives with superior properties.
- Website
-
http://www.hyphadiscovery.com
External link for Hypha Discovery Ltd
- Industry
- Research Services
- Company size
- 11-50 employees
- Headquarters
- Milton Park, Abingdon, Oxfordshire
- Type
- Privately Held
- Founded
- 2004
- Specialties
- Contract fermentation, Late stage hydroxylation, CYP metabolites, Non-CYP metabolites, Microbial natural products, Small molecule purification, Structure elucidation, Drug metabolites, Environmental fate metabolites, Metabolite kits, Metabolite purification, NMR, Metabolite synthesis, MetID, and Glucuronides
Locations
-
Primary
Get directions
154B Brook Drive,
Milton Park, Abingdon, Oxfordshire OX14 4SD, GB
Employees at Hypha Discovery Ltd
Updates
-
Great to see this paper out from a project undertaken for Repare Therapeutics in which we made an N-glucuronide of camonsertib by microbial biotransformation. Read more about the work at https://lnkd.in/dDgF5CTU. The publication is open access.
PUBLICATION ALERT: we are proud of our team and collaborators for continuing to advance our ATR inhibitor, camonsertib: In the first, we present a novel and comprehensive dose-finding strategy from the Phase I/IIa TRESR trial with Sarah Cannon Research Institute and Memorial Sloan Kettering Cancer Center. The second publication details the identification and biosynthesis of an N-glucuronide metabolite of camonsertib, the result of a seamless collaboration with Repare Therapeutics, Trimble Inc. Analytical Services, Hypha Discovery Ltd and BioAgilytix. Learn more here: https://lnkd.in/etJtE4Tb. #syntheticlethality #biotechcollaboration #precisiononcology
-
-
Liam Evans and Frank Scheffler are all set up for the start of CPHI in Philadelphia and looking forward to interesting discussions this week.
-
-
There's an interesting ACS-RSC-SCI Symposium on June 11th (12 noon ET / 9 am PT / 5 PM UK / 6 PM CET) - details below for tuning in. It'll be interesting to hear about the total synthesis of AZD5991 as Hypha made an acyl glucuronide of this compound using microbial biotransformation. The topics are: Total Synthesis of AZD5991 from a Process Chemistry Perspective - Oliver Ring, AstraZeneca Sweden. Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire - Sarah Reisman, California Institute of Technology Pasadena, USA. Symposium details - https://lnkd.in/evwkdYEt AZD5991 acyl glucuronide poster - https://lnkd.in/e7tHYgWA
-
Liam Evans and Frank Scheffler will be exhibiting at CPHI in Philadelphia from 7-9 May. Please reach out to them or visit booth 1402A if you're also planning to attend. More about CPHI North America at https://lnkd.in/gFYqAMm
-
-
The reasons for metabolite synthesis, the timing, and the methods used for their identification are all covered in our new review paper in Drug Discovery Today. The topic of our latest newsletter, the paper uses case studies to illustrate each area in the context of regulatory frameworks.
Drug Discovery Today publication
Hypha Discovery Ltd on LinkedIn
-
Our paper pick for April discusses the reasons and strategies for replacing a carboxylic acid with a bioisostere. Of particular interest is the authors use of structural biology to explore neutral bioisosteres that rely on less commonly explored cation π-interactions. Read more at https://lnkd.in/e24JD84B #drugdesign #medicinalchemistry #bioisosteres #drugmetabolism
-
-
Frank Scheffler will be at the 35th Symposium on Medicinal Chemistry in Eastern England being held at GSK in Stevenage on Thursday 25th March. Please drop by Booth 1 in the exhibit area to connect with Frank at the meeting. More info on the meeting at https://lnkd.in/egFZwa5u #medicinalchemistry #rsc
-
-
In this open access review just out in Drug Discovery Today we delve into the critical role of metabolites in drug discovery and the impact of regulatory frameworks. We look into the reasons for metabolite synthesis, the timing, and the methods used for their identification. Case studies illustrate the importance of understanding metabolite profiles, and underscore the need for timely assessment of metabolites. Access the paper at https://lnkd.in/efqxDWXW #drugmetabolism #biotransformation #medicinalchemistry #drugdiscovery #drugdevelopment
Small molecule drug metabolite synthesis and identification - Hypha Discovery
hyphadiscovery.com
-
Here's Hypha's new LinkedIn newsletter featuring our latest blog article and picks from the scientific literature so far this year. Please share if this is of interest with colleagues also curious about metabolites!
Metabolism of 2023 FDA Approved Small Molecules – PART 2
Hypha Discovery Ltd on LinkedIn